Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 298 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Naltrexone Clear all
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Not applicable Interventional Results available

Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone

NCT04762537
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Orlando, Florida • Rockville, Maryland • Cape Girardeau, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jun 10, 2026, 7:07 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

NCT05007561
View directory record Official record
Conditions
Naltrexone, Placebo
Interventions
Naltrexone Hydrochloride, Placebo
Drug
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Sweet Preference and Alcohol Craving

NCT01296646
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Abuse
Interventions
Naltrexone, Brenda Therapy Sessions, Placebo
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2010 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment of Alcohol Dependence

NCT00000452
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), Compliance Enhancement Tech., Cognitive Behavior Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 7:07 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional

Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence

NCT00332228
View directory record Official record
Conditions
Opiate Dependence
Interventions
depot naltrexone, Compliance enhancement (CE), BNT
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

NCT00366626
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jun 10, 2026, 7:07 AM EDT
Recruiting Phase 4 Interventional

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

NCT05919797
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone-Bupropion Combination
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jun 10, 2026, 7:07 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 4 Interventional

Biomarkers of Injectable Extended Release Naltrexone Treatment

NCT02324725
View directory record Official record
Conditions
Heroin Dependence, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Results available

ED Initiated Oral Naltrexone for AUD

NCT04817410
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Emergency Department Initiated Oral Naltrexone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 10, 2026, 7:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Yohimbine and Naltrexone on Sexual Function

NCT00042536
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Naltrexone HCL/ Yohimbine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional

Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1

NCT00238914
View directory record Official record
Conditions
Heroin Dependence
Interventions
Naltrexone, Behavioral Naltrexone Therapy (BNT), Compliance Enhancement (CE)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Jun 10, 2026, 7:07 AM EDT
Recruiting Early Phase 1 Interventional

Naltrexone Neuroimaging in Teens With Eating Disorders

NCT05509257
View directory record Official record
Conditions
Eating Disorders, Binge Eating, Purging (Eating Disorders), Bulimia Nervosa, Anorexia Nervosa, Atypical
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 10, 2026, 7:07 AM EDT
Recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Early Phase 1 Interventional

The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion

NCT00667771
View directory record Official record
Conditions
Alcohol Dependence, Alcoholism
Interventions
Naltrexone
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Naltrexone in Compulsive Sexual Behavior

NCT00467558
View directory record Official record
Conditions
Compulsive Sexual Behavior
Interventions
Naltrexone, Sugar pill
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

NCT03169816
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jun 10, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Harm Reduction With Pharmacotherapy (HaRP)

NCT01932801
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
XR-NTX, Placebo, HRC
Drug · Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 10, 2026, 7:07 AM EDT